295 related articles for article (PubMed ID: 23165461)
1. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
[TBL] [Abstract][Full Text] [Related]
2. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.
Lin HM; Wang JC; Hu HS; Wu PS; Yang CC; Wu CP; Pu SY; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yeh TK; Yueh A
Antimicrob Agents Chemother; 2012 Jan; 56(1):44-53. PubMed ID: 22006008
[TBL] [Abstract][Full Text] [Related]
3.
Asante-Appiah E; Liu R; Curry S; McMonagle P; Agrawal S; Carr D; Rokosz L; Lahser F; Bystol K; Chase R; Black S; Ferrari E; Ingravallo P; Tong L; Yu W; Kozlowski J
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150466
[TBL] [Abstract][Full Text] [Related]
4. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
[TBL] [Abstract][Full Text] [Related]
7. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
[TBL] [Abstract][Full Text] [Related]
8. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
[TBL] [Abstract][Full Text] [Related]
9.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals.
Nguyen LT; Hall N; Sheerin D; Carr M; De Gascun CF;
Antivir Ther; 2016; 21(5):447-53. PubMed ID: 26789637
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
[TBL] [Abstract][Full Text] [Related]
14. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
15. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
[TBL] [Abstract][Full Text] [Related]
16. A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro.
Cheng Y; Tsou LK; Cai J; Aya T; Dutschman GE; Gullen EA; Grill SP; Chen AP; Lindenbach BD; Hamilton AD; Cheng YC
Antimicrob Agents Chemother; 2010 Jan; 54(1):197-206. PubMed ID: 19901090
[TBL] [Abstract][Full Text] [Related]
17. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
[TBL] [Abstract][Full Text] [Related]
18. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
Uchida Y; Kouyama J; Naiki K; Sugawara K; Ando S; Nakao M; Motoya D; Inao M; Imai Y; Nakayama N; Mochida S
J Gastroenterol; 2016 Mar; 51(3):260-70. PubMed ID: 26245700
[TBL] [Abstract][Full Text] [Related]
19. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
